Use access key #2 to skip to page content.

September 2009

Recs

2

Morningstar on Big Pharma pipelines: Novartis best, Abbott worst

September 30, 2009 – Comments (2) | RELATED TICKERS: ABT , NVS , JNJ

Morningstar has an article evaluating the drug pipelines of Big Pharma. Basically, Novartis is the best overall and Abbott Labs is the worst. In terms of drugs in late-stage trials, GlaxoSmithKline and Johnson & Johnson do lead Novartis slightly; Novartis beats them in growth potential of present drugs. Pfizer and Merck/Schering trail slightly in late-stage drugs.   [more]

Recs

3

FASB Accounting rule change favors Apple, provides possible short term catalyst

September 28, 2009 – Comments (0) | RELATED TICKERS: AAPL

As Anders Bylund reports for TMF, Apple and some other tech firms lobbied FASB to allow them to recognize more revenue upfront when they sell products with extended contracts (e.g. iPhones). The traditional rules have penalized Apple to some degree, although Bylund argues (correctly) that they were perfectly appropriate for insurance firms, which need to reserve against losses and would probably game the system if they were allowed to book more premiums upfront. Insurers like MBIA aren't affected by the proposed FASB change.  [more]

Featured Broker Partners


Advertisement